Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
Publication
, Journal Article
Richman, B; Schulman, K; Greicius, M
Published in: JAMA
2021
Duke Scholars
Published In
JAMA
Publication Date
2021
Related Subject Headings
- Pharmacy Administration
- Marketing of Health Services
- Insurance, Pharmaceutical Services
- Insurance, Health
- Insurance Benefits
- Humans
- General & Internal Medicine
- Drug Prescriptions
- 42 Health sciences
- 32 Biomedical and clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Richman, B., Schulman, K., & Greicius, M. (2021). Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval? JAMA.
Richman, B., K. Schulman, and M. Greicius. “Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?” JAMA, 2021.
Richman B, Schulman K, Greicius M. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval? JAMA. 2021;
Richman, B., et al. “Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?” JAMA, 2021.
Richman B, Schulman K, Greicius M. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval? JAMA. 2021;
Published In
JAMA
Publication Date
2021
Related Subject Headings
- Pharmacy Administration
- Marketing of Health Services
- Insurance, Pharmaceutical Services
- Insurance, Health
- Insurance Benefits
- Humans
- General & Internal Medicine
- Drug Prescriptions
- 42 Health sciences
- 32 Biomedical and clinical sciences